Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HS-20093 vs Gemcitabine + Docetaxel in Osteosarcoma
NCT06935409Phase 3Completed
- Sponsor
- Hansoh Pharmaceutical Group
- Start
- Apr 2025
- Primary completion
- Jun 2026
- Modality
- Antibody-Drug Conjugates (ADCs)
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of risvutatug rezetecan in osteosarcoma (OS) (2 arms), sponsored by Hansoh Pharmaceutical Group. Primary endpoint: Progression-Free Survival assessed by IRC. Started Apr 2025; status: completed.
02
Drugs
risvutatug rezetecan
03
Conditions
osteosarcoma (OS)
Beyond the preview
Go deeper on NCT06935409.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06935409.